Quantitative EEG Correlates of Suicidal Behaviors in Children and Adolescents

Overview

Información sobre este estudio

The purpose of this study is to examine qEEG correlates of suicidal ideations and behaviors (SIBS) (screened by the Columbia-Suicide Severity Rating Scale (C-SSRS)) in hospitalized adolescents between the ages of 13-18 years as compared to age-matched healthy participants.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

For all participants

  • Ages 13-18;
  • Any gender, race or ethnicity;
  • Able to provide informed assent, and legal guardians able to provide informed consent if under 18 .

For patients

  • Being admitted to Generose 1-West with active suicidal ideations, suicidal behaviours (significant planning/preparation, attempt or aborted attempt) or non-suicidal self-injury.

Exclusion Criteria:

For all participants

  • Active co-morbid substance use meeting diagnostic criteria in MINI or MINI-KID (within the last month with the exception of caffeine and tobacco);
  • Neurological disorders including seizure disorder, anoxia history, history of head injuries with loss of consciousness for greater than 5 minutes;
  • Unable to read, speak or write English;
  • Refusal or withdrawal of consent, inability or unwillingness to adhere to study procedures.
  • Any non-removable hair extensions and or hair styling that would impede proper EEG recording;
  • Pregnancy or suspected pregnancy in female participants (assessed with urine pregnancy test).

For patients

  • Active psychosis or mania;
  • Autism spectrum disorder;
  • Intellectual disability;
  • Schizophrenic spectrum illness;
  • Antiepileptic medication use (valproic acid, carbamazepine, oxacarbamazapine, lamotrigine, gabapentin or topiramate), chronic benzodiazepine use or stimulant use (as needed benzodiazepine or stimulant use will be permitted if it can be held for at least 24 hour prior to the study visit);
  • Suicide attempt by significant overdose (requiring medical attention) with following group of medications:
    • benzodiazepines, antiepileptics, stimulants or attempt via hanging (asphyxiation) leading to anoxia.

For healthy participants

  • Any active or past psychiatric diagnoses screened by MINI/MINI-KID will be considered as exclusion criteria.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Paul Croarkin, D.O., M.S.

Cerrado para la inscripción

Contact information:

Deniz Doruk Camsari M.D.

(507)284-0557

Camsari.Deniz@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20450450

Mayo Clinic Footer